Artelo Biosciences, Inc. (NASDAQ:ARTL)

About the company

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Sector

Retail Trade

Industry

Catalog and Specialty Distribution

Employees

4

CEO

Gregory D. Gorgas

Exchange

NASDAQ

Website

http://www.artelobio.com

$NoneM

Total Revenue

4

Employees

$3.87M

Market Capitalization

-0.84

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Artelo Biosciences, Inc. ARTL 3.87 None 1.19 -0.84 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds

9d ago, source: Business Insider

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics ...

ARTL Artelo Biosciences, Inc. Common Stock

12d ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

BRIEF-Artelo Biosciences Expands Stony Brook Commercial License Agreement

9d ago, source: Reuters

ARTELO BIOSCIENCES EXPANDS STONY BROOK COMMERCIAL LICENSE AGREEMENT FOR FABP5 PLATFORM FOR DEVELOPMENT OF LEAD CANCER, PAIN AND INFLAMMATION COMPOUNDS Source text for Eikon: Further company coverage: ...

Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences

1mon ago, source: YAHOO!

LA JOLLA, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and ...

Artelo Biosciences Inc.

16d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

ARTL Artelo Biosciences, Inc. Common Stock

12d ago, source: Nasdaq

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds

9d ago, source: wallstreet online

LA JOLLA, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.